Caveat emptor: Direct-to-consumer supply and advertising of genetic testing

Clinical and Investigative Medicine

Volumn 27, Issue 1, 2004, Pages 23-32

  Mykitiuk, Roxanne ^a  

^a YORK UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERTIZING; CLINICAL GENETICS; CONFERENCE PAPER; CONSUMER; GENETIC ANALYSIS; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HEALTH SERVICE; HUMAN; INTERNET; PHYSICIAN; PRIORITY JOURNAL; REGULATORY MECHANISM;

GENETICS AND REPRODUCTION;

ADVERTISING; BIOTECHNOLOGY; BREAST NEOPLASMS; CANADA; ETHICS, MEDICAL; FEMALE; GENETIC COUNSELING; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; MARKETING OF HEALTH SERVICES; MASS SCREENING;

EID: 1842739564     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (37)

1. Williams-Jones B. Where there's a web, there's a way: commercial genetic testing and the Internet. Community Genet 2003;6:46-57.
2. Williams-Jones B. Re-framing the discussion: commercial genetic testing in Canada. Health Law J 1999;7:49-67.
3. Caulfield T, Feasby C. The commercialization of human genetics in Canada: an overview of policy and legal issues. In: Knoppers BM, editor. Socio-ethical issues in human genetics. Cowansville (QC): Yvon Blais; 1998. p. 345-6.
4. Caulfield T, Wertz D. Creating needs? A review of survey data and concerns relevant to the commercialization of genetic testing. Community Genet 2001;4:68-76.
5. Provincial Advisory Committee on New Predictive Genetic Technologies. Genetics services in Ontario: mapping the future. Toronto: Ontario Ministry of Health and Long-Term Care; 2001.
6. Holtzman NA, Shapiro D. The new genetics: genetic testing and public policy. BMJ 1998;316(7134):852-6.
7. Burgess MM. Marketing and fear-mongering: Is it time for commercialized genetic testing?" In: Caulfield TA, Williams-Jones B, editors. The commercialization of genetics research: ethical, legal, and policy issues. New York: Kluwer Academic/Plenum Publishers; 1999. p. 181.
8. Caulfield TA, Burgess MM, Williams-Jones B, Baily MA, Chadwick R, Cho M, et al. Providing genetic testing through the private sector: a view from Canada. ISUMA Can J Policy Res 2001;2(3):72-81.
9. Human Genetics Commission. Genes direct: ensuring the effective oversight of genetic tests supplied directly to the public. London, UK: Department of Health; 2003.
10. Task Force on Genetic Information and Insurance. Genetic information and health insurance. Washington: National Institutes of Health; 1993.
11. Lemmens T, Bahamin P. Genetics in life, disability and additional health insurance in Canada: a comparative legal and ethical analysis. In: Knoppers BM, editor. Socio-ethical issues in human genetics. Cowansville (QC): Yvon Blais; 1998.
12. Australian Law Reform Commission and Australian Health Ethics Committee. Protection of human genetic information. Issues paper 26. Sydney: Commonwealth of Australia; 2001.
13. Bosompra K, Ashikaga T, Flynn BS, Worden JK, Solomon LJ. Psychosocial factors associated with the public's willingness to pay for genetic testing for cancer risk: a structural equations model. Health Educ Res 2001;16:157-72.
14. Burgess MM, Hayden MR. Patients' rights to laboratory data: trinucleotide repeat length in Huntington disease. Am J Med Genet 1996;62:6-9.
15. Cox SM, McKellin W. "There's this thing in our family": predictive testing and the construction of risk for Huntington disease. Social Health Illn 1999;21:622-46.
16. Wertz DC. Patients' and professionals' view on autonomy, disability and discrimination: results of a 36-nation survey. In: Caulfield TA, Williams-Jones B, editors. The commercialization of genetics research: ethical, legal, and policy issues. New York: Kluwer Academic/Plenum Publishers; 1999.
17. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM. Promotion of prescription drugs to consumers. N Engl J Med 2002;346:498-505.
18. Gollust SE, Hull SC, Wilfond BS. Limitation of direct-to-consumer advertising for clinical genetic testing. JAMA 2002;288:1762-7.
19. Harper PS. Direct marketing of cystic fibrosis carrier screening: commercial push or population need? J Med Genet 1995;32:249-50.
20. Hull SC, Prasad K. Reading between the lines: direct-to-consumer advertising of genetic testing in the USA. Reprod Health Matters 2001;9(18):44-8.
21. Evans JP, Skrzynia C, Burke W. The complexities of predictive testing. BMJ 2001;322:1052-6.
22. Emery J, Hayflick S. The challenge of integrating genetic medicine into primary care. BMJ 2001;322:1027-30.
23. Codori AM. Psychological opportunities and hazards in predictive genetic testing for cancer risk. Gastroenterol Clin North Am 1997;26:19-39.
24. Wolfe SM. Direct-to-consumer advertising - education or emotion promotion. N Engl J Med 2002;346:524-6.
25. Caulfield TA. Gene testing in the biotech century: Are physicians ready? CMAJ 1999;161(9):1122-4.
26. James CA, Geller G, Bernhardt BA, Docksum T, Holtzman NA. Are practicing and future physicians prepared to obtain informed consent? The case of genetic testing for susceptibility to breast cancer. Community Genet 1998;1:203-12.
27. Mintzes B. The truth, the half truth, and nothing like the truth: regulation and drug promotion in Canada In: Barer ML, McGrail KM, Cardiff K, Wood L, Green CJ, editors. Tales from the other drug wars. Vancouver: BC Centre for Health Services and Policy Research; 2000. p. 55-64.
28. Graham J. Harbinger of hope or commodity fetishism: "re- cognizing" dementia in an age of therapeutic agents. Int Psychogeriatr 2001;13:131-4.
29. Lee TH, Brennan TA. Direct-to-consumer marketing of high-technology screening tests. N Engl J Med 2002;346:529-31.
30. Hull SC, Prasad K. Direct-to-consumer advertising of genetic testing. Hastings Cent Rep 2001;31(3):33-5.
31. Peppin P, Carty E. Semiotics, stereotypes, and women's health: signifying inequality in drug advertising. Can J Women Law 2001;13:326-60.
32. Why women should be wary of direct advertising of drugs. Straight Goods 2002 Aug. 6. Available: www .straightgoods.ca/viewConsForum.cfm?REF=259 (accessed 2002 September).
33. Food and Drugs Act, R.S.C. 1985, c. F-27.
34. Broadcasting Act, 1991, c.11.
35. Medical Devices Regulations, S.O.R. 1998-282, Sch. I, R. 4(b).
36. Brill-Edwards M. Canada's health protection branch: Whose health, what protection? In: Barer ML, McGrail KM, Cardiff K, Wood L, Green CJ, editors. Tales from the other drug wars. Vancouver: B.C. Centre for Health Services and Policy Research; 2000.
37. Pharmaceutical Advertising Advisory Board (PAAB). Code of advertising acceptance. Pickering, Ont.: PAAB; 2002. Available: www.paab.ca/code_en.pdf (accessed 2003 Jan 7).